Blood cancers have helped shape the evolution of cancer treatment from the beginning. As early as World War II, the first chemotherapies were developed to help people living with lymphoma.1 Following those early approaches, we’ve experienced a revolution in our understanding of the genomic drivers of hematologic malignancies that has led to the development of a range of new targeted therapies. With recent advances in comprehensive genomic profiling (CGP), we are now poised to further impact the treatment landscape for blood cancers.
Blood cancers can affect people at any stage of life. For example, leukemia is the most common cancer in children and teens, but our knowledge of the genomic drivers of pediatric cases and how they could help predict treatment responses is limited.2 We need more information on the relationship between genomic markers and survival outcomes in these types of blood cancers to improve our understanding of these drivers.
At this year’s American Society of Hematology (ASH) Annual Meeting, we are pleased to present new data on how CGP may improve accuracy of diagnosis or aid in therapy selection in pediatric leukemias, as well as help identify significant biologic differences in pediatric versus adult acute myeloid leukemia.
Our FoundationOne® Heme CGP assay is specific to hematologic cancers and sarcomas and is able to uncover clinically relevant information in blood cancers. Analysis of cases previously profiled using FoundationOne®Heme has revealed that 77 percent of blood cancers analyzed harbored at least one molecular alteration linked to a molecularly targeted therapy that is either commercially available or in clinical development.3
We believe that understanding the genomic complexity of blood cancers can help us guide treatment decisions for patients of all ages.
Learn more about some of the data to be showcased at ASH this year, which addresses different indications such as acute myeloid leukemia (AML), pediatric AML, multiple myeloma (MM) and follicular lymphoma (FL):
- Poster: Comprehensive Genomic Profiling for Improved Diagnosis and Therapy of Pediatric Acute Leukemias
- Oral: Comprehensive Clinical Genomic Profiling Defines Age-Associated Molecular Targets in Pediatric and Adult Acute Myeloid Leukemia
- Oral: A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments
- Oral: Aberrant Phosphorylation of MEF2C Is Dispensable for Hematopoiesis, and Induces Chemotherapy Resistance and Susceptibility to MARK Kinase Inhibition Therapy in Acute Myeloid Leukemia
- Poster: High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1
- Oral: Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets